InVivo Therapeutics Holdings Corp. (NVIV), a biomaterials company with
innovative technologies for drug delivery with a focus on treatment of
spinal cord injuries, today announced that it has closed an underwritten
public offering of 12,175,000 shares of common stock and warrants to
purchase up to an aggregate of 6,087,500 shares of common stock, at a
price of $1.15 per share of common stock and $0.00001 per warrant. The
warrants have a per share exercise price of $1.4375, 125% of the public
offering price of the common stock, are exercisable immediately, and
expire five years from the date of issuance. In addition, the
underwriter exercised its entire over-allotment option to purchase an
additional 1,826,250 shares of common stock and warrants to purchase an
additional 913,125 shares of common stock.
InVivo received gross proceeds from the offering of approximately $16.1
million, before deducting underwriting discounts and commissions and
other estimated offering expenses and assuming no exercise of warrants.
InVivo anticipates using the net proceeds from this offering for general
corporate purposes, including for research, development and pre-clinical
studies for its product candidates, completion of its scaffold pilot
clinical study, and working capital.
Aegis Capital Corp. acted as sole book-running manager for the offering.
This offering was made pursuant to an effective shelf registration
statement that the Company previously filed with the Securities and
Exchange Commission (SEC) and was declared effective on January 19,
2012. A final prospectus supplement and accompanying base prospectus
relating to the offering has been filed with the SEC and is available on
the SEC’s website, www.sec.gov.
Copies of the final prospectus supplement and the accompanying base
prospectus relating to this offering, when available, may be obtained
from Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue,
18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy any securities, nor shall there be any
sale of these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.
About InVivo Therapeutics Holdings Corp.
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials company
with unique technologies for drug delivery with a focus on treatment of
spinal cord injuries. The Company was founded in 2005 with proprietary
technology co‐invented by Robert Langer, ScD., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
is affiliated with Massachusetts General Hospital. In 2011, the Company
earned the David S. Apple Award from The American Spinal Injury
Association for its outstanding contribution to spinal cord injury
medicine. The publicly traded company is headquartered in Cambridge, MA.
For more details, visit, www.invivotherapeutics.com.
Forward-Looking Statements
Statements made in this press release that do not describe historical
facts or which apply prospectively are “forward-looking statements”
within the meaning of the federal securities laws. These statements can
be identified by words such as “believe,” “anticipate,” “intend,”
“estimate,” “will,” “may,” “should,” “expect” and similar expressions,
and relate to future events or the Company’s future operating or
financial performance and include statements regarding InVivo’s intended
use of the proceeds from the offering. Any forward-looking statements
contained herein are based on current expectation, and are subject to a
number of risks and uncertainties. Given these uncertainties, investors
should not place undue reliance on these forward-looking statements.
Factors that could cause actual results to differ materially from
current expectations include whether InVivo can complete the scaffold
pilot clinical study, the success of the scaffold pilot clinical study,
and InVivo’s ability to execute its business plan. Additional risk
factors are included in InVivo’s prospectus supplement related to this
offering, InVivo’s Annual Report on Form 10-K for the year ended
December 31, 2013, as amended, and other filings InVivo makes with the
SEC, including quarterly reports on Form 10-Q and current reports on
Form 8-K. InVivo does not undertake to update these forward-looking
statements.
Copyright Business Wire 2014